Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone and melatonin for hypoxic brain injury after resuscitated cardiopulmonary arrest
IRCT20190215042716N9Phase 2Not yet recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of edaravone and melatonin in hypoxic-ischemic encephalopathy (HIE) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: All-cause mortality at 28 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
edaravonemelatonin
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on IRCT20190215042716N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190215042716N9.